Trials / Completed
CompletedNCT00002148
Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the tolerability and safety of OPC-14117. To evaluate effects of OPC-14117 on cognitive function, quality of life, and activities of daily living.
Detailed description
Patients receive OPC-14117 or placebo bid for 12 weeks, followed by 12 weeks of open label therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPC 14117 |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002148. Inclusion in this directory is not an endorsement.